SH-053-R-CH3-2′F (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "SH-053-R-CH3-2′F" in English language version.

refsWebsite

Global rank English rank

4^th place

4^th place

2^nd place

2^nd place

1patents.google.com

1,182^nd place

725^th place

doi.org

Savić MM, Huang S, Furtmüller R, Clayton T, Huck S, Obradović DI, et al. (January 2008). "Are GABAA receptors containing alpha5 subunits contributing to the sedative properties of benzodiazepine site agonists?". Neuropsychopharmacology. 33 (2): 332–339. doi:10.1038/sj.npp.1301403. PMID 17392731.
Savić MM, Clayton T, Furtmüller R, Gavrilović I, Samardzić J, Savić S, et al. (May 2008). "PWZ-029, a compound with moderate inverse agonist functional selectivity at GABA(A) receptors containing alpha5 subunits, improves passive, but not active, avoidance learning in rats". Brain Research. 1208: 150–159. doi:10.1016/j.brainres.2008.02.020. PMC 2577822. PMID 18394590.
Stamenić TT, Poe MM, Rehman S, Santrač A, Divović B, Scholze P, et al. (November 2016). "Ester to amide substitution improves selectivity, efficacy and kinetic behavior of a benzodiazepine positive modulator of GABA_A receptors containing the α5 subunit". European Journal of Pharmacology. 791: 433–443. doi:10.1016/j.ejphar.2016.09.016. PMC 5107132. PMID 27639297.
Prevot TD, Li G, Vidojevic A, Misquitta KA, Fee C, Santrac A, et al. (April 2019). "Novel Benzodiazepine-Like Ligands with Various Anxiolytic, Antidepressant, or Pro-Cognitive Profiles". Molecular Neuropsychiatry. 5 (2): 84–97. doi:10.1159/000496086. PMC 6528097. PMID 31192221.

nih.gov

pubmed.ncbi.nlm.nih.gov

Savić MM, Huang S, Furtmüller R, Clayton T, Huck S, Obradović DI, et al. (January 2008). "Are GABAA receptors containing alpha5 subunits contributing to the sedative properties of benzodiazepine site agonists?". Neuropsychopharmacology. 33 (2): 332–339. doi:10.1038/sj.npp.1301403. PMID 17392731.
Savić MM, Clayton T, Furtmüller R, Gavrilović I, Samardzić J, Savić S, et al. (May 2008). "PWZ-029, a compound with moderate inverse agonist functional selectivity at GABA(A) receptors containing alpha5 subunits, improves passive, but not active, avoidance learning in rats". Brain Research. 1208: 150–159. doi:10.1016/j.brainres.2008.02.020. PMC 2577822. PMID 18394590.
Stamenić TT, Poe MM, Rehman S, Santrač A, Divović B, Scholze P, et al. (November 2016). "Ester to amide substitution improves selectivity, efficacy and kinetic behavior of a benzodiazepine positive modulator of GABA_A receptors containing the α5 subunit". European Journal of Pharmacology. 791: 433–443. doi:10.1016/j.ejphar.2016.09.016. PMC 5107132. PMID 27639297.
Prevot TD, Li G, Vidojevic A, Misquitta KA, Fee C, Santrac A, et al. (April 2019). "Novel Benzodiazepine-Like Ligands with Various Anxiolytic, Antidepressant, or Pro-Cognitive Profiles". Molecular Neuropsychiatry. 5 (2): 84–97. doi:10.1159/000496086. PMC 6528097. PMID 31192221.

ncbi.nlm.nih.gov

Savić MM, Clayton T, Furtmüller R, Gavrilović I, Samardzić J, Savić S, et al. (May 2008). "PWZ-029, a compound with moderate inverse agonist functional selectivity at GABA(A) receptors containing alpha5 subunits, improves passive, but not active, avoidance learning in rats". Brain Research. 1208: 150–159. doi:10.1016/j.brainres.2008.02.020. PMC 2577822. PMID 18394590.
Stamenić TT, Poe MM, Rehman S, Santrač A, Divović B, Scholze P, et al. (November 2016). "Ester to amide substitution improves selectivity, efficacy and kinetic behavior of a benzodiazepine positive modulator of GABA_A receptors containing the α5 subunit". European Journal of Pharmacology. 791: 433–443. doi:10.1016/j.ejphar.2016.09.016. PMC 5107132. PMID 27639297.
Prevot TD, Li G, Vidojevic A, Misquitta KA, Fee C, Santrac A, et al. (April 2019). "Novel Benzodiazepine-Like Ligands with Various Anxiolytic, Antidepressant, or Pro-Cognitive Profiles". Molecular Neuropsychiatry. 5 (2): 84–97. doi:10.1159/000496086. PMC 6528097. PMID 31192221.

patents.google.com

CA 3016491, Cook JM, Li G, Poe M, Savic M, Sibille E, "Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing gabaa receptor agonists."